Assessment of breast tumour [Na+] using 23Na magnetic resonance imaging: a potential diagnostic biomarker for malignant disease

Research output: Contribution to conferenceAbstract

Standard

Assessment of breast tumour [Na+] using 23Na magnetic resonance imaging: a potential diagnostic biomarker for malignant disease. / James, Andrew; Kaggie, Joshua D.; Riemer, Frank; Baxter, Gabrielle; McLean, Mary; Leslie, Theresa; Nelson, Michaela; Gallagher, Ferdia A.; Gilbert, Fiona J.; Kennerley, Aneurin James; Brackenbury, Will.

2020. 533 Abstract from UK Interdisciplinary Breast Cancer Symposium, Birmingham, United Kingdom.

Research output: Contribution to conferenceAbstract

Harvard

James, A, Kaggie, JD, Riemer, F, Baxter, G, McLean, M, Leslie, T, Nelson, M, Gallagher, FA, Gilbert, FJ, Kennerley, AJ & Brackenbury, W 2020, 'Assessment of breast tumour [Na+] using 23Na magnetic resonance imaging: a potential diagnostic biomarker for malignant disease', UK Interdisciplinary Breast Cancer Symposium, Birmingham, United Kingdom, 27/01/20 - 28/01/20 pp. 533. https://doi.org/10.1007/s10549-019-05514-3

APA

James, A., Kaggie, J. D., Riemer, F., Baxter, G., McLean, M., Leslie, T., Nelson, M., Gallagher, F. A., Gilbert, F. J., Kennerley, A. J., & Brackenbury, W. (2020). Assessment of breast tumour [Na+] using 23Na magnetic resonance imaging: a potential diagnostic biomarker for malignant disease. 533. Abstract from UK Interdisciplinary Breast Cancer Symposium, Birmingham, United Kingdom. https://doi.org/10.1007/s10549-019-05514-3

Vancouver

James A, Kaggie JD, Riemer F, Baxter G, McLean M, Leslie T et al. Assessment of breast tumour [Na+] using 23Na magnetic resonance imaging: a potential diagnostic biomarker for malignant disease. 2020. Abstract from UK Interdisciplinary Breast Cancer Symposium, Birmingham, United Kingdom. https://doi.org/10.1007/s10549-019-05514-3

Author

James, Andrew ; Kaggie, Joshua D. ; Riemer, Frank ; Baxter, Gabrielle ; McLean, Mary ; Leslie, Theresa ; Nelson, Michaela ; Gallagher, Ferdia A. ; Gilbert, Fiona J. ; Kennerley, Aneurin James ; Brackenbury, Will. / Assessment of breast tumour [Na+] using 23Na magnetic resonance imaging: a potential diagnostic biomarker for malignant disease. Abstract from UK Interdisciplinary Breast Cancer Symposium, Birmingham, United Kingdom.1 p.

Bibtex - Download

@conference{e749ba4653bd450ebd018345cfbca361,
title = "Assessment of breast tumour [Na+] using 23Na magnetic resonance imaging: a potential diagnostic biomarker for malignant disease",
abstract = "Introduction: Despite advances in early stage disease treatment, metastatic breast cancer has poor prognosis. Evidence indicates that malignant tumours exhibit elevated [Na+]. Moreover, evidence sug- gests that this [Na+] elevation reduces following response to neoadjuvant chemotherapy. Numerous studies implicate an altered ionic microenvironment in tumour progression. Indeed, triple-nega- tive breast cancer cells (MDA-MB-231) aberrantly express voltage- gated sodium channels (VGSCs); these facilitate an inward Na+ current, leading to elevated intracellular [Na+] ([Na+]i) and increased invasiveness.Aims/Objectives: Using 23Na magnetic resonance imaging approa- ches, we assessed the utility of tumour [Na+] as a novel diagnostic indicator for malignant disease.Methods: We developed a bespoke radiofrequency coil for a 7T preclinical magnetic resonance imaging (MRI) system and measured tumour [Na+] in a xenograft mouse model of triple-negative breast cancer. Endpoint tumour [Na+] was confirmed using inductively coupled plasma mass spectrometry (ICP-MS). Na+ conductance within live tumour slices was assessed using the whole-cell patch clamp method. To measure tumour [Na+] in patients with breast cancer, a protocol was developed for a clinical 3T MRI system (MR750, GE Healthcare) using a 4-channel 23Na/16-channel 1H coil. Results: 23Na imaging and ICP-MS revealed elevated [Na+] in xenograft tumours compared with healthy mammary tissue. Standard chemotherapy (docetaxel, 10 mg/kg i.p. weekly) inhibited tumour growth rate and decreased tumour [Na+] compared with control. However, docetaxel had no effect on Na+ conductance within live tumour slices. The antiepileptic medication eslicarbazepine acetate (VGSC blocker, 200 mg/kg p.o. daily) had no effect on tumour growth, tumour [Na+], or Na+ conductance. Our clinical imaging approach was validated on healthy volunteers and recruitment for the clinical study has begun.Conclusions: Elevated tumour [Na+] in breast cancer may represent a potential imaging biomarker for malignancy and response to chemotherapy. Moreover, targeting of elevated tumour [Na+] should be investigated as a potential treatment avenue.",
author = "Andrew James and Kaggie, {Joshua D.} and Frank Riemer and Gabrielle Baxter and Mary McLean and Theresa Leslie and Michaela Nelson and Gallagher, {Ferdia A.} and Gilbert, {Fiona J.} and Kennerley, {Aneurin James} and Will Brackenbury",
year = "2020",
month = feb,
day = "6",
doi = "10.1007/s10549-019-05514-3",
language = "English",
pages = "533",
note = "UK Interdisciplinary Breast Cancer Symposium, UKIBCS ; Conference date: 27-01-2020 Through 28-01-2020",

}

RIS (suitable for import to EndNote) - Download

TY - CONF

T1 - Assessment of breast tumour [Na+] using 23Na magnetic resonance imaging: a potential diagnostic biomarker for malignant disease

AU - James, Andrew

AU - Kaggie, Joshua D.

AU - Riemer, Frank

AU - Baxter, Gabrielle

AU - McLean, Mary

AU - Leslie, Theresa

AU - Nelson, Michaela

AU - Gallagher, Ferdia A.

AU - Gilbert, Fiona J.

AU - Kennerley, Aneurin James

AU - Brackenbury, Will

PY - 2020/2/6

Y1 - 2020/2/6

N2 - Introduction: Despite advances in early stage disease treatment, metastatic breast cancer has poor prognosis. Evidence indicates that malignant tumours exhibit elevated [Na+]. Moreover, evidence sug- gests that this [Na+] elevation reduces following response to neoadjuvant chemotherapy. Numerous studies implicate an altered ionic microenvironment in tumour progression. Indeed, triple-nega- tive breast cancer cells (MDA-MB-231) aberrantly express voltage- gated sodium channels (VGSCs); these facilitate an inward Na+ current, leading to elevated intracellular [Na+] ([Na+]i) and increased invasiveness.Aims/Objectives: Using 23Na magnetic resonance imaging approa- ches, we assessed the utility of tumour [Na+] as a novel diagnostic indicator for malignant disease.Methods: We developed a bespoke radiofrequency coil for a 7T preclinical magnetic resonance imaging (MRI) system and measured tumour [Na+] in a xenograft mouse model of triple-negative breast cancer. Endpoint tumour [Na+] was confirmed using inductively coupled plasma mass spectrometry (ICP-MS). Na+ conductance within live tumour slices was assessed using the whole-cell patch clamp method. To measure tumour [Na+] in patients with breast cancer, a protocol was developed for a clinical 3T MRI system (MR750, GE Healthcare) using a 4-channel 23Na/16-channel 1H coil. Results: 23Na imaging and ICP-MS revealed elevated [Na+] in xenograft tumours compared with healthy mammary tissue. Standard chemotherapy (docetaxel, 10 mg/kg i.p. weekly) inhibited tumour growth rate and decreased tumour [Na+] compared with control. However, docetaxel had no effect on Na+ conductance within live tumour slices. The antiepileptic medication eslicarbazepine acetate (VGSC blocker, 200 mg/kg p.o. daily) had no effect on tumour growth, tumour [Na+], or Na+ conductance. Our clinical imaging approach was validated on healthy volunteers and recruitment for the clinical study has begun.Conclusions: Elevated tumour [Na+] in breast cancer may represent a potential imaging biomarker for malignancy and response to chemotherapy. Moreover, targeting of elevated tumour [Na+] should be investigated as a potential treatment avenue.

AB - Introduction: Despite advances in early stage disease treatment, metastatic breast cancer has poor prognosis. Evidence indicates that malignant tumours exhibit elevated [Na+]. Moreover, evidence sug- gests that this [Na+] elevation reduces following response to neoadjuvant chemotherapy. Numerous studies implicate an altered ionic microenvironment in tumour progression. Indeed, triple-nega- tive breast cancer cells (MDA-MB-231) aberrantly express voltage- gated sodium channels (VGSCs); these facilitate an inward Na+ current, leading to elevated intracellular [Na+] ([Na+]i) and increased invasiveness.Aims/Objectives: Using 23Na magnetic resonance imaging approa- ches, we assessed the utility of tumour [Na+] as a novel diagnostic indicator for malignant disease.Methods: We developed a bespoke radiofrequency coil for a 7T preclinical magnetic resonance imaging (MRI) system and measured tumour [Na+] in a xenograft mouse model of triple-negative breast cancer. Endpoint tumour [Na+] was confirmed using inductively coupled plasma mass spectrometry (ICP-MS). Na+ conductance within live tumour slices was assessed using the whole-cell patch clamp method. To measure tumour [Na+] in patients with breast cancer, a protocol was developed for a clinical 3T MRI system (MR750, GE Healthcare) using a 4-channel 23Na/16-channel 1H coil. Results: 23Na imaging and ICP-MS revealed elevated [Na+] in xenograft tumours compared with healthy mammary tissue. Standard chemotherapy (docetaxel, 10 mg/kg i.p. weekly) inhibited tumour growth rate and decreased tumour [Na+] compared with control. However, docetaxel had no effect on Na+ conductance within live tumour slices. The antiepileptic medication eslicarbazepine acetate (VGSC blocker, 200 mg/kg p.o. daily) had no effect on tumour growth, tumour [Na+], or Na+ conductance. Our clinical imaging approach was validated on healthy volunteers and recruitment for the clinical study has begun.Conclusions: Elevated tumour [Na+] in breast cancer may represent a potential imaging biomarker for malignancy and response to chemotherapy. Moreover, targeting of elevated tumour [Na+] should be investigated as a potential treatment avenue.

U2 - 10.1007/s10549-019-05514-3

DO - 10.1007/s10549-019-05514-3

M3 - Abstract

SP - 533

T2 - UK Interdisciplinary Breast Cancer Symposium

Y2 - 27 January 2020 through 28 January 2020

ER -